Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 5426 Gefitinib (Iressa) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been shown to be clinically effective in a subpopulation of non small cell lung cancer (NSCLC) patients. Despite initial responses to gefitinib in some NSCLC patients, cancer eventually progresses by unknown mechanisms of acquired resistance. We explored the use of the novel tumor suppressor FUS1 to enhance the chemotherapeutic potency of gefitinib and overcome gefitinib resistance in NSCLC. We found that reactivation of wild-type FUS1 by FUS1 nanoparticle-mediated gene transfer into FUS1-deficient and gefitinib-resistant NSCLC H1299, H322, H358, and H460 cells significantly ( P < 0.001) sensitized their response to gefitinib treatment and synergistically induced apoptosis in vitro and in an H322 orthotopic lung cancer mouse model. To understand the mechanism of gefitinib-induced resistance, we established a gefitinib-resistant HCC827GR NSCLC cell line (IC50 = 16 μM) by selecting against gefitinib from the parental HCC827 cells that contain an activating deletion mutation of the EGFR gene and are extremely sensitive to gefitinib treatment (IC50 = 0.016 μM). We found no secondary mutations in the EGFR gene in the HCC827GR cells, but these cells registered a significantly elevated level of phosphorylated AKT protein. Combination treatment with FUS1 nanoparticles and gefitinib at a dose level of IC10 significantly re-sensitized the cells to gefitinib, as demonstrated by synergistically enhanced growth inhibition and apoptosis. FUS1 nanoparticle treatment alone or with gefitinib markedly inactivated EGFR and AKT, as demonstrated by decreased phosphorylation levels of both proteins on Western blots, compared with either agent alone. Cleavage of caspase-3, caspase-9, and PARP was also significantly induced by the combination of FUS1 and gefitinib in HCC872GR and other gefitinib-resistant NSCLC cells. Our results suggest that a combination treatment of FUS1 nanoparticles and gefitinib could overcome drug-induced resistance by simultaneously inactivating EGFR and the AKT signaling pathway and by facilitating apoptosis. This abstract is supported by grants from NCI (SPORE P50CA70907) and DOD (TARGET, DAMD17002-1-0706).

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.

GLRX Inhibition Enhances the Effects of Geftinib in EGFR-TKI-resistant NSCLC Cells Through FoxM1 Signaling Pathway

Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth

Overcoming Gefitinib Resistance in Nsclc Via Inactivation of the Pi3k/Akt Signaling Pathway by A Combination of Fus1 Nanoparticles and Egfr Inhibitors.

Inhibition of Autophagy by YC-1 Promotes Gefitinib Induced Apoptosis by Targeting FOXO1 in Gefitinib-Resistant NSCLC Cells

YC-1 Potentiates the Antitumor Activity of Gefitinib by Inhibiting HIF-1α and Promoting the Endocytic Trafficking and Degradation of EGFR in Gefitinib-Resistant Non-Small-cell Lung Cancer Cells

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.

Geranylgeranyl transferase 1 inhibitor GGTI‑298 enhances the anticancer effect of gefitinib.

Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Combined Inhibition Of The Egfr And Mtor Pathways In Egfr Wild-Type Non-Small Cell Lung Cancer Cell Lines With Different Genetic Backgrounds

Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

JAK2 Inhibitor TG101348 Overcomes Erlotinib-Resistance in Non-Small Cell Lung Carcinoma Cells with Mutated EGF Receptor

3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer*

Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells